摘要
目的探讨替吉奥+奥沙利铂+阿帕替尼方案对Ⅳ期胃癌患者转化治疗的效果。方法依据给药方案将112例Ⅳ期胃癌患者分为二联组(n=55)和三联组(n=57),二联组患者给予替吉奥+奥沙利铂方案治疗,三联组患者给予替吉奥+奥沙利铂+阿帕替尼方案治疗。比较两组患者的临床疗效、生活质量[生命质量测定量表体系之胃癌量表(QLICP-ST)]、不良反应、手术转化率、R_(0)切除率和随访1年生存率。结果三联组患者的总缓解率为42.11%,明显高于二联组患者的18.18%(P﹤0.01),临床控制率为71.93%,高于二联组患者的49.09%(P﹤0.05)。三联组患者手足综合征、高血压发生率均高于二联组(P﹤0.05)。治疗后,两组患者QLICP-ST量表各维度评分及总分均高于本组治疗前(P﹤0.05),且三联组患者QLICP-ST量表评分及总分均高于二联组(P﹤0.05)。三联组患者手术转化率和R_(0)切除率均明显高于二联组(P﹤0.01),两组患者随访1年生存率无明显差异(P﹥0.05)。结论替吉奥+奥沙利铂+阿帕替尼方案对Ⅳ期胃癌患者的转化治疗效果显著,可提高总缓解率、临床控制率,改善患者的生活质量,提高手术转化率和R0切除率,且不良反应轻微。
Objective To investigate the effect of ticgio+oxaliplatin+apatinib regimen on translational therapy for patients with stage IV gastric cancer.Method A total of 112 patients with stage Ⅳ gastric cancer were divided into the double groups(n=55)and the triple groups(n=57)according to the chemotherapy plan.Patients in the double groups were treated with ticgio+oxaliplatin regimen,and patients in the triple group were given ticgio+oxaliplatin+apatinib regimen.The clinical effect,quality of life[quality of life instruments for cancer patients-stomach cancer(QLICP-ST)],adverse events,surgical translational rate,R0 resection rate,and 1-year follow-up survival were compared between the two groups of patients.Result The total response rate of patients in the triple group was 42.11%,which was significantly higher than 18.18% in the double group(P<0.01),and the clinical control rate was 71.93%,which was higher than 49.09% in the double group(P<0.05).The incidence of the hand-foot syndrome and hypertension in the triple group was higher than that in the double group(P<0.05).After the treatment,the QLICP-ST scale scores and total scores of the two groups of patients were higher than themselves before the treatment(P<0.05),and the QLICP-ST scale scores and total scores of patients in the triple group were higher than those in the double group(P<0.05).The surgical conversion rate and R_(0) resection rate of patients in the triple group were significantly higher than those in the double group(P<0.01),and there was no significant difference in the 1-year survival between the two groups(P>0.05).Conclusion The ticgio+oxaliplatin+apatinib regimen has a remarkable effect on translational therapy for patients with stage Ⅳ gastric cancer.The combined plan could increase the overall objective response rate,clinical control rate,and improve the quality of life of patients.Besides,it can increase the surgical translational rate and R_(0) resection rate with mild adverse events.
作者
吴天峰
林春丽
崔杰
WU Tianfeng;LIN Chunli;CUI Jie(Department of Oncology,First People’s Hospital of Shangqiu,Shangqiu 476000,He’nan,China)
出处
《癌症进展》
2021年第23期2428-2431,共4页
Oncology Progress
关键词
胃癌
替吉奥
奥沙利铂
阿帕替尼
转化治疗
gastric cancer
ticgio
oxaliplatin
apatinib
translational therapy
